References
- Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. Food and Drug Administration News Release. 2010 Oct 19. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. Accessed 2011 Nov 4.
- Product Information: PRADAXA(R) oral capsules, dabigatran etexilate mesylate oral capsules. Boehringer Ingelheim Pharmaceuticals, Inc.
- Palladino M, Thomson L, Swift B, Merli GJ. Implementing the new oral anticoagulants into the hospital formulary. Am J Hematol 2012; 87:S127–S132.
- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–1151.
- Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, . Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation 2011; 123:2363–2372.
- Kaiser C. Pradaxa bleeding deaths raise concern. MedPage Today 2011 Nov 2. Available at http://www.medpagetoday.com/Cardiology/Strokes/29411. Accessed 2011 Nov 4.
- Bachmakov I, Rekersbrink S, Hofmann U, Eichelbaum M, Fromm MF. Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein. N Schmied Arch Pharmacol 2005; 371:195–201.
- Schwarz U, Gramatte T, Krappweis T, Oertel R, Kirch W. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 2000; 38:161–167.
- van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of direct thrombin inhibitor Dabigatran, by recombinant factor VIIa ore activated prothrombin complex concentrations. Haematologica 2008; 93:148–0370 (abstract).
- Van Ryn J, Stangier J, Haertter S. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116–1127.